Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01006)
Name	Dinoprostone
Synonyms	Click to Show/Hide the Synonyms of This API Prostaglandin E2; Dinoprostone; PGE2; 363-24-6; Prostin E2; Prepidil; Cervidil; Propess; Minprositin E2; Minprostin E2; Dinoproston; Prostin; (15S)-Prostaglandin E2; Prostarmon E; Dinoprostonum; l-Prostaglandin E2; Dinoprostona; Glandin; l-PGE2; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; U-12062; (-)-Prostaglandin E2; Prostaglandin E; UNII-K7Q1JQR04M; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; NSC 165560; [3H]PGE2; U 12062; [3H]prostaglandin E2; CHEMBL548; NSC 196514; K7Q1JQR04M; 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; CHEBI:15551; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, l-; PGE2alpha; Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-; MFCD00077861; Prostaglandin E(2); NSC-165560; NSC-196514; (Z)-7-[(1r,2r,3r)-3-Hydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]-5-Oxo-Cyclopentyl]hept-5-Enoic Acid; NCGC00092361-05; Prostaglandin E2alpha; Prostaglandin E2.alpha.; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; DSSTox_CID_2947; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-; DSSTox_RID_76801; DSSTox_GSID_22947; Dinoprostonum [INN-Latin]; U-12,062; 9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid; Dinoprostona [INN-Spanish]; Cerviprime; Prostenone; Enzaprost E; 7-[3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoic acid; Prostarmon E2; Cervidil (TN); Prepidil (TN); (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid; CAS-363-24-6; Dinoprostone Prostaglandin E2; U,062; Prostin E2 (TN); PGE2-[3,3,4,4-d4]; SR-05000001459; EINECS 206-656-6; Dinoprostone (JAN/USP/INN); (5Z,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; BML1-F07; Prosta-5, (5Z,11.alpha.,13E,15S)-11,15-dihydroxy-9-oxo-; Prosta-5, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-; Prosta-5, 11,5-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-; [3H]dinoprostone; 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-; prosta-glandin e2; NCGC00092361-06; (E,2R,3R)-7-[3-hydroxy-2-[(3S)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]-5-heptenoic acid; P2E; Prestwick_793; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; [3H]prostin E2; BMS-279654 & PGE2; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostone [USAN:USP:INN:BAN:JAN]; Prostaglandin E2, 98%; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; SCHEMBL25533; BSPBio_001490; GTPL1883; GTPL1916; DTXSID4022947; [3H]-PGE2; BDBM35847; HMS1361K12; HMS1791K12; HMS1989K12; HMS2089D17; HMS3268J12; HMS3402K12; HMS3413C20; HMS3648F07; HMS3677C20; (Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid; AMY30102; EX-A1773; ZINC3830713; Tox21_111196; LMFA03010003; NSC165560; NSC196514; s3003; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; AKOS015920228; Tox21_111196_1; AC-6098; CCG-208092; CCG-208256; CS-6932; DB00917; IDI1_033960; Prosta-5,13-dien-1-oic acid, (5Z,11-alpha,13E,15S)-11,15-dihydroxy-9-oxo-; SMP2_000056; NCGC00092361-01; NCGC00092361-02; NCGC00092361-03; NCGC00092361-04; AS-71847; HY-101952; B7005; P1884; 1798-EP2272832A1; 1798-EP2277848A1; 1798-EP2277858A1; 1798-EP2295055A2; 1798-EP2298767A1; 1798-EP2301922A1; 1798-EP2305641A1; 1798-EP2305653A1; 1798-EP2308510A1; 1798-EP2308872A1; 1798-EP2311453A1; 1798-EP2311808A1; 1798-EP2311829A1; 1798-EP2314574A1; 1798-EP2314587A1; 1798-EP2316829A1; C00584; D00079; Prostaglandin E2, >=93% (HPLC), synthetic; 363P246; Q416554; SR-01000946417; J-502620; SR-01000946417-1; SR-05000001459-1; SR-05000001459-3; SR-05000001459-4; BRD-K26521938-001-04-9; 05D31BD5-818B-4A92-8CFC-BEC19926A5B3; 2-AMINO-1-BENZO[1,3]DIOXOL-5-YL-ETHANONEHYDROCHLORIDE; Dinoprostone, European Pharmacopoeia (EP) Reference Standard; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoic acid; (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoate; Dinoprostone, United States Pharmacopeia (USP) Reference Standard; (5Z,11?,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1oic acid; (5Z,11I+/-,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoic acid; Prostaglandin E2, synthetic, powder, BioReagent, suitable for cell culture; (5Z,11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-o xo-prosta-5,13-dien-1oic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)- (8CI); Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-; Prostaglandin E2, gamma-irradiated, powder, BioXtra, suitable for cell culture
Clinical Status	Approved
PubChem CID	5280360
Formula	C20H32O5
Canonical SMILES	CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
InChI	1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
InChIKey	XEYBRNLFEZDVAW-ARSRFYASSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5280360"></iframe>
Structure	3D MOL		2D MOL
Physicochemical Properties	Molecular Weight	352.5	Topological Polar Surface Area	94.8
	XlogP	2.8	Complexity	469
	Heavy Atom Count	25	Rotatable Bond Count	12
	Hydrogen Bond Donor Count	3	Hydrogen Bond Acceptor Count	5

Full List of Drug Formulations (DFMs) Containing This API
Dinoprostone 10mg extended release insert			Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Polyethylene Oxide; Urethane Polymer
Dosage Form	Extended Release Insert
Company	Ferring Pharmaceuticals
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Polyethylene glycol 4000	DIG Info	Albendazole monooxygenase (Inhibition ratio < 40 %)	[1]
Dinoprostone 0.5mg/3gm gel			Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Colloidal Silicon Dioxide Nf; Triacetin Usp
Dosage Form	Gel
Company	Pfizer

References
1	Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.